1. Scrip
  2. >>Business
  3. >>Earnings

Good News For AbbVie: Allergan's Q2 Sales Exceed Expectations, Including Behemoth Botox

 
• By Mandy Jackson

AbbVie is buying Allergan for its product sales, both to increase its own revenues and to fund future R&D and business development, so Allergan's Q2 gains are good news.

Businessman draws a statistical trend line
Q2 Botox sales rose and Restasis held up much better than expected. • Source: Shutterstock

Allergan PLC posted better than expected product sales for the second quarter on 6 Aug. with its blockbusters Botox (onabotulinumtoxinA) and Restasis (cyclosporine) holding up well versus competitive pressures. Yet despite the good news for AbbVie Inc., which is paying $63bn for Allergan primarily for its Botox-fueled revenue stream, the companies still can't shake external concerns that the top-selling wrinkle reducer's sales won't hold up over time.

Investors have good reason to worry, since Botox is facing new competition in its two biggest categories – medical aesthetics...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Japan Results Roundup: Reduced Forex Impact, Uncertain US Tariff Outlook

 
• By Lisa Takagi

Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.

S&E In Brief: Launch Updates And Political Headwinds

 
• By Sushmita Panda

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.

Lupin Confident Of US Growth On Tariff Mitigation, Rides High On Tolvaptan

 
• By Vibha Ravi

Lupin is hoping moves like intellectual property transfer for some products to the US will help mitigate the tariff impact even as it counts on growth from planned launches of GLP-1s and biosimilars while riding high on tolvaptan launched in Q1.

Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win

 
• By Alaric DeArment

The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.

More from Business

Japan Results Roundup: Reduced Forex Impact, Uncertain US Tariff Outlook

 
• By Lisa Takagi

Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 
• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

S&E In Brief: Launch Updates And Political Headwinds

 
• By Sushmita Panda

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.